The Myeloma Sessions: Post-ASH 2020 UK Discussion

The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…

Date: 19th April 2021

The Post-EBMT for Trainees VJSessions

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of…

Date: 15th April 2021

The Myeloma Sessions: Post-ASH 2020 UK Discussion

The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…

Date: 19th April 2021

The Post-EBMT for Trainees VJSessions

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of…

Date: 15th April 2021

Post-ASH Amyloidosis Session from VJHemOnc

The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…

Date: 13th April 2021

The Post-EBMT VJSessions from VJHemOnc

The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…

Date: 7th April 2021

Post-EBMT highlights in acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be…

Date: 6th April 2021

The CLL Sessions: highlights from ASH 2020

Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….

Date: 17th March 2021

The Lymphoma Sessions: highlights from ASH 2020

Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for…

Date: 17th March 2021

The MDS Sessions: Giants in MDS

The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the…

Date: 17th March 2021

Latest therapies in AML: IMGN632, magrolimab & gilteritinib

The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as…

Date: 16th March 2021

VJSession: EBMT/EHA CAR-T Nursing Session

The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European…

Date: 23rd February 2021

The Myeloma Sessions: key updates from ASH 2020

Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…

Date: 22nd February 2021

The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs

Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many…

Date: 19th February 2021

Updates for the management of MDS from ASH 2020

During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the…

Date: 16th February 2021

The AML Sessions: highlights from ASH 2020

Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm…

Date: 16th February 2021

The MDS Sessions: treating MDS around the world

The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS…

Date: 12th February 2021

Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data

Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…

Date: 5th February 2021

Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020

Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically…

Date: 28th January 2021

Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of…

Date: 20th January 2021

Advances in CAR T-cell therapies for lymphoma from ASH 2020

Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into…

Date: 18th January 2021

Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells…

Date: 11th January 2021

The MDS sessions: lower-risk disease

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…

Date: 7th December 2020

The AML Sessions: FLT3-mutated disease

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases,…

Date: 27th November 2020

The Lymphoma Sessions: highlights from iwNHL 2020

This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL)…

Date: 18th November 2020

The MDS sessions: clinical trial participation, endpoints & approvals

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…

Date: 17th November 2020

The AML Sessions: Venetoclax-based regimens

The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms…

Date: 12th November 2020

The AML Sessions: IDH inhibitors

IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown…

Date: 3rd November 2020

The AML Sessions: Immunotherapy

Acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in…

Date: 8th October 2020

Latest transplant updates from EBMT 2020

Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease…

Date: 1st October 2020

Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is…

Date: 1st October 2020

SOHO 2020: Next questions in hematological malignancies

The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…

Date: 25th September 2020

The MPN Sessions: pathobiology, therapeutic strategies & clinical trials

Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more…

Date: 15th September 2020

Latest AML therapies: novel preparations and first in class agents

Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported…

Date: 14th September 2020

Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells

Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin…

Date: 10th September 2020

CLL: MRD and first-in class agents

Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the…

Date: 13th August 2020

The Myeloma Sessions: Evolving management of myeloma & COVID-19

Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high…

Date: 6th August 2020

MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls

It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been…

Date: 6th August 2020

The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies

A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of…

Date: 31st July 2020

The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…

Date: 28th July 2020

The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML

The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment…

Date: 16th July 2020

Key updates in ALL at EHA 2020

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater…

Date: 7th July 2020

The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)…

Date: 3rd July 2020

Systemic mastocytosis: current landscape, novel agents and COVID-19

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…

Date: 2nd June 2020

MRD assessment in AML: incorporation into clinical practice

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable…

Date: 22nd April 2020

Myeloma management in the COVID-19 era

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians…

Date: 14th April 2020

CAR-T in the CLL space

Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients…

Date: 2nd April 2020

CAR T-cell therapy & multiple myeloma: past, present & future

CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable…

Date: 2nd April 2020

Harnessing the tumor microenvironment in lymphoma therapy

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into…

Date: 2nd April 2020

CLL therapy: the latest trial updates and innovative novel therapies for the future

Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential…

Date: 20th September 2019

Precision epigenetic therapy for B-cell lymphoma

Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus,…

Date: 18th July 2019

Induction therapy in myeloma: an ever-changing paradigm

In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…

Date: 18th July 2019

iwAL 2019: looking to the future of acute leukemia therapy

The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods…

Date: 6th June 2019

Acute leukemia: pushing boundaries in disease management

This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology…

Date: 6th June 2019

CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma

Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges….

Date: 18th December 2018

MRD testing in multiple myeloma: new technology with promising clinical applications

Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…

Date: 23rd November 2018

CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence

CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…

Date: 11th October 2018

Patient discussion at EHA 2018: CAR T-cells and MRD in CLL

CAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL)…

Date: 14th September 2018

CLL therapies today: novel agents, combinations & the future of the field

Chronic lymphocytic leukemia (CLL) is experiencing a revolution in its treatment approaches. New therapies are constantly in development, and the…

Date: 20th August 2018

CAR T-cell therapy: where are we now and what’s in store for the future?

Over the last several years, CAR T-cell therapy has emerged as a revolution in immunotherapy, with incredible results to date….

Date: 25th July 2018

Focus on MRD: current landscape and future questions in hemonc

Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting….

Date: 4th July 2018

Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?

A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…

Date: 16th March 2018

Acute leukemias: is MRD already a surrogate for survival?

The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…

Date: 9th March 2018

Revolutionary immunotherapies for lymphoma

Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new…

Date: 2nd February 2018

Latest advances and current challenges in immunotherapies for lymphoma

In this lively discussion, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System and George Washington University,…

Date: 15th December 2017

The circle of CLL: from gene discovery to targeted treatment

In this exciting feature, Carlo Croce, MD, from Ohio State University, Columbus, OH, provides an overview of the history of…

Date: 8th December 2017

Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances

This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…

Date: 16th November 2017

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…

Date: 16th November 2017

Debate on the use of MRD for multiple myeloma management

The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…

Date: 16th November 2017

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter